PINOTBIO is a biotech that develops new treatments for patients who are resistant to existing treatments based on innovative new drug modalities such as Antibody Drug Conjugates (ADCs). Based on its strong R&D capabilities, it has independently built PINOT-ADC™, a next-generation ADC platform, and is concentrating on researching new anti-cancer ADC drugs with various partners. In addition, clinical development and commercial...
PINOTBIO is a biotech that develops new treatments for patients who are resistant to existing treatments based on innovative new drug modalities such as Antibody Drug Conjugates (ADCs). Based on its strong R&D capabilities, it has independently built PINOT-ADC™, a next-generation ADC platform, and is concentrating on researching new anti-cancer ADC drugs with various partners. In addition, clinical development and commercialization of NTX-301, a target anti-cancer drug for blood cancer/solid cancer, and NTX-101, a glaucoma treatment, are in progress.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.